Compare Medpace Holdings Inc (MEDP) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Under Armour Inc Class A — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Under Armour Inc Class A trades at $4.92 (market cap $2.07B). The key difference: Medpace Holdings Inc is far larger — about 8.1× Under Armour Inc Class A's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Under Armour Inc Class A for 99 Days on average.
| MEDP | UAA | |
|---|---|---|
Market Cap | $16.82B | $2.07B |
Volume | 223,093 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $8.14 |
52-Week Low | $393.42 | $4.17 |
Typical Hold Time | 14 Days | 99 Days |
Enterprise Value | $16.44B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Under Armour (UAA) trades at $4.94, up 2.49% today, as the company navigates a challenging turnaround. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while technical indicators show a bullish trend despite negative profitability metrics. The company faces revenue declines but maintains margin improvement focus, with analyst consensus leaning toward Hold amid ongoing transformation efforts.
The outlook remains cautious with revenue weakness offset by cost discipline. Investment opportunity exists if margin gains translate to sustained profitability, but risks include persistent demand softness and high debt levels. Current valuation appears reasonable with P/S of 0.42, though negative ROE and net margins warrant careful monitoring of the brand transformation progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
